US OptionsDetailed Quotes
JSPR250117P22500
- 14.80
- 0.000.00%
15min DelayClose Jan 10 16:00 ET
0.00High0.00Low
14.80Open14.80Pre Close0 Volume19 Open Interest22.50Strike Price0.00Turnover546.10%IV-9.22%PremiumJan 17, 2025Expiry Date15.45Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9087Delta0.0341Gamma0.45Leverage Ratio-0.0609Theta-0.0026Rho-0.41Eff Leverage0.0015Vega
Jasper Therapeutics Stock Discussion
Sign in to post a comment
NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NE...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NE...
104
32
15
$Jasper Therapeutics (JSPR.US)$ Why the share price plummeted despite good progress in their research outcome?
$Jasper Therapeutics (JSPR.US)$
Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria
Wednesday, 8th January at 7:00 am
Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile
Mean change in UAS7 from baseline of -26.6 observed in the 240mg single dose cohort at 8 weeks, multiple dosing regimens ≥120mg demonstrated UAS7 change of more than -25 points
100% (N=3) Com...
Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria
Wednesday, 8th January at 7:00 am
Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile
Mean change in UAS7 from baseline of -26.6 observed in the 240mg single dose cohort at 8 weeks, multiple dosing regimens ≥120mg demonstrated UAS7 change of more than -25 points
100% (N=3) Com...
1
big sell-off to trick people into selling, stock is going to Boom
$Jasper Therapeutics (JSPR.US)$ good time to buy back in cheap
$Jasper Therapeutics (JSPR.US)$ rise time, $15 by end of day
1
No comment yet
151158967 : Thank you, @Jaguar8 . Your hard work is appreciated!
103687630 : I think, what do you think of ONDS? There was good news on Wednesday but it went down. Do you think there is a chance for a rebound?
Jaguar8 OP 103687630 : I didn’t choose it because it didn’t specify how much is the contract.
103687630 Jaguar8 OP : Okay, thank you for your reply
70761249 : Can VERI make a breakthrough in the short term? The recent wildfires in Southern California are really heartbreaking, causing significant disappointment in the credibility of the media and government.
View more comments...